According to The Insight Partners, the Multiple Sclerosis Therapeutics Market was valued at US$ 24,026.90 million in 2019 and is projected to reach US$ 39,223.59 million by 2027, growing at a CAGR of 6.5% from 2020 to 2027. The growth outlook reflects increasing demand for therapies that can slow disease progression, manage symptoms, and improve patient quality of life. The report identifies the rising prevalence of multiple sclerosis as a major growth driver. MS affects the central nervous system, and its symptoms can include weakness, sensory abnormalities, vision problems, muscle stiffness, cognitive difficulties, and urinary complications. Increasing diagnosis and recognition of the disease are expanding the addressable patient population and supporting demand for long-term pharmacological treatment.
Multiple Sclerosis Therapeutics Market Size, Share, Trends, Analysis, and Forecast by 2034
Although the cited Insight Partners report provides its forecast through 2027, the following points summarize the principal market indicators and long-term factors relevant to assessing the market outlook toward 2034:
- Market Size: The market was valued at US$ 24,026.90 million in 2019 and is projected to reach US$ 39,223.59 million by 2027.
- Market Growth: The global market is expected to expand at a 6.5% CAGR from 2020 to 2027.
- North America Share: North America held the largest regional share, accounting for 38.1% in 2019.
Download Sample PDF – https://www.theinsightpartners.com/sample/TIPRE00004057
- US Growth: The US is projected to grow at a 7% CAGR during the forecast period.
- Drug Class Trend: Immunomodulators represented the largest drug-class segment, with a 57.3% share in 2019, while immunosuppressants are expected to register a higher CAGR during the forecast period.
- Route of Administration: Injectable therapies held the larger share in 2019 and are anticipated to record a 6.9% CAGR during the forecast period.
- Distribution Channel: Hospital pharmacies accounted for the largest share at 59.3% in 2019, while e-commerce is anticipated to register the highest CAGR.
- Long-Term Outlook to 2034: Continued disease prevalence, therapeutic innovation, broader access to treatment, and pharmaceutical product development are expected to support sustained expansion beyond the report’s 2027 forecast horizon. The source report does not provide a verified 2034 market-size or CAGR figure, so a specific 2034 value should not be inferred from the published data.
Market Drivers and Trends
The increasing prevalence of multiple sclerosis remains one of the most important factors supporting therapeutic demand. The report notes that approximately 1 million adults in the US were estimated to be living with MS based on National Multiple Sclerosis Society research cited by the report. Canada also had more than 77,000 people living with MS according to government estimates cited by The Insight Partners. These trends highlight the continuing requirement for disease management and long-term treatment.
Another important trend is the growing use of disease-modifying therapies. Immunomodulators held the largest share among drug classes in 2019, supported by the adoption of these therapies and the availability of new generic drugs. Meanwhile, immunosuppressants are expected to experience comparatively faster growth. Pharmaceutical companies are also emphasizing product innovation and portfolio expansion to respond to changing treatment requirements and strengthen their competitive positions.
The market is also evolving through changes in administration and distribution. Injectable therapies remain important because of their established role in MS treatment, while oral therapies provide an alternative that can improve convenience for appropriate patients. Hospital pharmacies remain a major distribution channel, but the anticipated rapid expansion of e-commerce indicates increasing digitalization in pharmaceutical purchasing and distribution.
Regional Analysis
North America dominated the global market in 2019 with a 38.1% share, supported by a developed healthcare ecosystem, high disease awareness, advanced diagnostic capabilities, and strong pharmaceutical infrastructure. The US is expected to remain a major growth engine, with a projected 7% CAGR. Canada represents another important regional market because of its established healthcare system and sizeable MS patient population. Mexico contributes to the regional landscape as healthcare access and pharmaceutical availability continue to develop.
Europe remains a significant market because of established healthcare systems and the presence of major pharmaceutical companies. Asia Pacific is expected to demonstrate particularly strong momentum, with the report projecting a 7.2% CAGR over the forecast period. Increasing healthcare expenditure, expanding access to neurological care, and growing disease awareness are expected to create additional opportunities across the region. South and Central America and the Middle East & Africa also represent emerging opportunities as healthcare infrastructure and treatment accessibility improve.
Market Segmentation Analysis
The Multiple Sclerosis Therapeutics Market is segmented by drug class, route of administration, distribution channel, and geography. By drug class, the market includes immunosuppressants and immunomodulators. By route of administration, it is divided into injectable and oral therapies. By distribution channel, the market comprises hospital pharmacies, retail pharmacies, and e-commerce. Geographically, the analysis covers North America, Europe, Asia Pacific, South and Central America, and the Middle East & Africa.
Key Players
- Bayer AG
- F. Hoffmann-La Roche Ltd
- Merck & Co Inc
- Teva Pharmaceutical Industries Ltd
- Novartis AG
- Sanofi SA
- Bristol-Myers Squibb Co
- Takeda Pharmaceutical Co Ltd
- Horizon Therapeutics plc
- Biogen Inc
These companies are profiled in the report in the context of competitive positioning, product innovation, portfolio development, and strategies designed to address changing demand for MS therapies.
Get Premium Research Report Market Size and Report at:
https://www.theinsightpartners.com/buy/TIPRE000040
About Us
The Insight Partners is an one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish
